The ongoing pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with a greater number of deaths occurring more rapidly than had been observed among previously leading causes of mortality, such as unintentional injuries, stroke and heart diseases. As of July 6, 2020, more than 11,495,412 confirmed cases have been reported, along with more than 535,185 officially notified deaths. 1 In developing countries, specific data regarding incidence, local clinical manifestations, radiological and laboratory abnormalities and requirements for establishment of differential diagnoses considering local peculiarities still remain obscure and are often insufficient. In Brazil, as of June 15, 2020, 1,603,055 cases and 64,867 deaths had been legally counted. 1 So far, according to studies conducted in developed countries, the typical signs and symptoms of the novel 2019 coronavirus are fever, coughing (with or without sputum), sore throat, and shortness of breath (with or without associated respiratory distress comprising oxygen saturation < 95.0%). 2,3 However, new symptomatic profiles are being described in the literature, almost on a daily basis. Manifestations such as acute olfactory disorders, acute hyposmia and anosmia, dysgeusia and dermatological complaints might also be present with the onset of coronavirus disease (COVID-19). 4-7 Although several studies have already described symptom profiles for patients in European and Asian-Pacific countries, at present there is no study providing detailed information within the Brazilian populational setting. Indeed, few papers on COVID-19 symptom profiles